Scarica l'app Stockscreener
5.05
3.48%
0.17
Pre-mercato:
4.90
-0.15
-2.97%
Taysha Gene Therapies Inc Borsa (TSHA) Ultime notizie
Why Taysha Gene Therapies Inc. stock is favored by top institutionsMarket Volume Report & Long-Term Investment Growth Plans - newser.com
Taysha Gene Therapies stock rating reiterated at Market Outperform by Citizens - Investing.com Canada
Earnings visualization tools for Taysha Gene Therapies Inc.Weekly Trading Summary & Fast Entry Momentum Trade Alerts - newser.com
Why Taysha Gene Therapies Inc. is moving today2025 Price Action Summary & Weekly High Return Forecasts - newser.com
Has Taysha Gene Therapies Inc. formed a bullish divergenceJuly 2025 Decliners & Low Drawdown Investment Strategies - newser.com
Collegium Pharmaceutical, Inc. (COLL): A Bull Case Theory - MSN
Tick level data insight on Taysha Gene Therapies Inc. volatilityJuly 2025 Sentiment & Free Reliable Trade Execution Plans - newser.com
What MACD and RSI say about Taysha Gene Therapies Inc.2025 Volume Leaders & Smart Allocation Stock Tips - newser.com
Can Taysha Gene Therapies Inc. stock hit record highs again2025 Volatility Report & Verified Entry Point Signals - newser.com
Is Taysha Gene Therapies Inc. trending in predictive chart modelsPortfolio Return Report & Consistent Income Trade Ideas - newser.com
Weiss Ratings Reiterates Sell (D-) Rating for Taysha Gene Therapies (NASDAQ:TSHA) - MarketBeat
Taysha Gene Therapies Hits Day High with 7.2% Surge in Stock Price - Markets Mojo
Taysha Gene Therapies (TSHA) Reveals Enhanced Trial Results for Rett Syndrome - GuruFocus
Taysha Gene Therapies Presents New Supplemental Data Analysis from Part A of the REVEAL Phase 1/2 Trials for TSHA-102 in Rett Syndrome at the 54th CNS Annual Meeting - The Manila Times
Taysha Gene Therapies Presents New Supplemental Data - GlobeNewswire
Taysha's TSHA-102 Shows 100% Response in Phase 1/2 Rett Trial | TSHA Stock News - Stock Titan
Will Taysha Gene Therapies Inc. stock continue dividend increasesMarket Sentiment Summary & Technical Entry and Exit Tips - newser.com
Analyzing net buyer seller activity in Taysha Gene Therapies Inc.Weekly Trade Analysis & Growth Oriented Trading Recommendations - newser.com
Visual analytics tools that track Taysha Gene Therapies Inc. performanceEarnings Beat & Daily Technical Stock Forecast Reports - newser.com
Taysha Gene Therapies Hits Day Low of $4.40 Amid Price Pressure - Markets Mojo
Taysha Gene Therapies, Inc. Sees Revision in Stock Evaluation Amid Strong Market Performance - Markets Mojo
Taysha soars on FDA breakthrough therapy status for lead asset - MSN
Taysha Gene Therapies (NASDAQ:TSHA) Trading Down 4.9%Time to Sell? - MarketBeat
Taysha Gene Therapies Hits New 52-Week High at $5.40 - Markets Mojo
Taysha Gene Therapies: Breakthrough Rett Program With BLA Acceleration Potential (TSHA) - Seeking Alpha
Will Taysha Gene Therapies Inc. stock maintain growth story2025 Trading Volume Trends & Fast Moving Market Watchlists - newser.com
How to interpret RSI for Taysha Gene Therapies Inc. stockWeekly Trade Analysis & Low Volatility Stock Recommendations - newser.com
Taysha Snags FDA Breakthrough Therapy Designation for Rett Syndrome Gene Therapy TSHA-102 - CGTLive®
How Recent Developments Are Rewriting the Story for Taysha Gene Therapies - Yahoo Finance
Taysha Gene Therapies (TSHA) Gets a Buy from Canaccord Genuity - The Globe and Mail
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Needham & Company LLC Issues Positive Forecast for Taysha Gene Therapies (NASDAQ:TSHA) Stock Price - Defense World
Best Small Cap Stocks To Add to Your Watchlist – October 2nd - Defense World
Taysha Gene Therapies stock hits 52-week high at 5.05 USD - Investing.com Nigeria
1.29M-option grant: Taysha grants 1,289,600 stock options at $3.18, 4-yr vesting under Nasdaq rule - Stock Titan
US FDA Backing Is A Breakthrough For Taysha’s Gene Therapy - insights.citeline.com
Taysha Gene Therapies (NASDAQ:TSHA) Sees Unusually-High Trading Volume After Analyst Upgrade - MarketBeat
BMO Capital Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Maintains Target Price $5 - 富途牛牛
A Quick Look at Today's Ratings for Taysha Gene Therapies(TSHA.US), With a Forecast Between $8 to $14 - 富途牛牛
Taysha Gene Therapies Announces January 2022 Virtual Investor Events to Review Preliminary Clinical Data for TSHA-101 in GM2 Gangliosidosis and High Dose Cohort and Long-Term Clinical Data for TSHA-120 in Giant Axonal Neuropathy | FinancialCont - FinancialContent
Taysha Gene Therapies Stock Soars To 3-Year High After FDA Boost — Wall Street Calls Rett Drug ‘Derisked’ And Ahead Of Rivals - Stocktwits
Could Taysha's FDA Alignment Fast-Track Its BLA Submission? - RTTNews
Robert W. Baird Issues Positive Forecast for Taysha Gene Therapies (NASDAQ:TSHA) Stock Price - Defense World
Analyzing drawdowns of Taysha Gene Therapies Inc. with statistical toolsJuly 2025 Big Picture & Smart Allocation Stock Tips - newser.com
1.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):